Physician profile
George Yu
NPI 1245231968
$11,874.10
in general payments reported to CMS, 2019-2025
34 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $1,379 · 2021: $1,666 · 2022: $1,916 · 2023: $1,615 · 2024: $1,304 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Consulting Fee: $350 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,304.08 |
| Consulting Fee | $350.00 |
| Education | $150.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,592.23 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,933.54 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Mylan Specialty L.P. | $972.54 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $803.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $797.84 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Inspire Medical Systems, INC. | $584.63 | 2019-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $559.25 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $515.63 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $500.03 | 2024-2025 | Lumryz |
| Insmed, INC. | $322.95 | 2019-2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $245.12 | 2019-2024 | Prolastin-C Liquid |
| Pfizer INC. | $233.84 | 2019-2025 | |
| Viatris Specialty LLC | $205.57 | 2025 | Yupelri |
| United Therapeutics Corporation | $178.80 | 2022-2023 | Tyvaso |
| Arbor Pharmaceuticals, INC. | $166.42 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $143.72 | 2022-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Advanced Respiratory, INC | $138.23 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $129.19 | 2023-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $121.88 | 2024-2025 | Horizant, Alvesco |
| Genentech USA, INC. | $121.69 | 2019-2020 | |
| Intuitive Surgical, INC. | $114.81 | 2023 | Da Vinci Surgical System |
| Axsome Therapeutics, INC. | $109.59 | 2022-2025 | Sunosi |
| Sunovion Pharmaceuticals INC. | $90.06 | 2019 | |
| Lilly USA, LLC | $56.96 | 2025 | Zepbound |
| Genzyme Corporation | $41.88 | 2019-2021 | |
| Phadia US INC. | $34.39 | 2022-2024 | Immunocap |
| Itamar Medical INC | $30.71 | 2023 | Watchpatone |
| Electromed, INC. | $28.88 | 2021-2022 | |
| Zoll Respicardia, INC. | $22.56 | 2025 | Remede System |
| Optinose US, INC. | $19.82 | 2024 | |
| Amgen INC. | $17.73 | 2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $14.63 | 2019 | |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Eisai INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.